Prevalence and Risk Factors of Pulmonary Embolism in COPD Patients Complicated with Secondary Polycythemia
Jimei Li,Yulin Xiong,Shengyan Li,Qiong Ye,Yan Han,Xiuxin Zhang,Tongxiu Zhao,Yuan Yang,Xiaoshan Cui,Yinglan Li
DOI: https://doi.org/10.2147/copd.s481905
2024-11-04
International Journal of COPD
Abstract:Jimei Li, &ast Yulin Xiong, &ast Shengyan Li, Qiong Ye, Yan Han, Xiuxin Zhang, Tongxiu Zhao, Yuan Yang, Xiaoshan Cui, Yinglan Li General Medicine Department, Qinghai Provincial People's Hospital, Xining, Qinghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yinglan Li, General Medicine Department, Qinghai Provincial People's Hospital, Gonghe Road 2, Xining, Qinghai, People's Republic of China, Tel +8613997233103, Email Purpose: This study aimed to establish the prevalence of pulmonary embolism (PE) in chronic obstructive pulmonary disease (COPD) patients with secondary polycythemia (SP) and explore the risk factors for PE in COPD patients with SP. Patients and Methods: We analyzed the prevalence of PE among COPD patients with SP who were hospitalized at Qinghai Provincial People's Hospital between January 2015 and December 2020. From January 2021 to January 2024, we enrolled patients into three groups (COPD+SP+PE, COPD+SP, and control) and performed laboratory measurements, biomarkers, echocardiography, and pulmonary function tests. Patients in the COPD+SP group received clinical treatment, and biomarkers were measured again seven days after treatment. Results: The prevalence of PE in patients with COPD SP was 5.21%. We found that COPD+SP+PE group had significantly higher levels of erythrocyte distribution width (RDW), platelet volume distribution width (PDW), mean platelet volume (MPV), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), monocyte to large platelet ratio (MLPR), 5-hydroxytryptamine (5-HT), activated protein C (APC), urokinase-type plasminogen activator (u-PA), thrombomodulin (TM), interleukin-38 (IL-38), tissue factor (TF), and fractalkine (FKN) in contrast to COPD+SP group. Biomarkers, such as FKN, β-thromboglobulin (β-TG), APC, u-PA, TM, TF, and IL-38, were risk factors for COPD patients with SP who are complicated by PE. Clinical treatment significantly reduced the levels of β-TG, IL-38, APC, endothelin-1 (ET-1), u-PA, FKN, TM, 5-HT, and neutrophil extracellular traps (NETs) in patients with COPD+SP. Conclusion: PE incidence was significantly higher in patients with COPD and SP. In COPD patients with SP, routine joint detection of blood and cardiac markers, blood gas analysis, and pulmonary function tests can help to identify patients with PE. APC, u-PA, TF, FKN, TM, and IL-38 are risk factors for PE in patients with COPD and SP, and clinical treatment can effectively reduce this risk. Keywords: chronic obstructive pulmonary diseases, secondary polycythemia, pulmonary embolism, biomarker, risk factors Chronic obstructive pulmonary disease (COPD) is an important public health challenge and major cause of chronic morbidity and mortality throughout the world. 1 It is characterized by persistent respiratory symptoms and airflow limitation and is related to an enhanced chronic inflammatory response of the airways and lungs to noxious particles or gases. 2 Secondary polycythemia (SP) is a comorbidity of COPD due to chronic and chronic sustained hypoxia, and its prevalence in patients with COPD is approximately 2–10%, 3,4 which is closely associated with an increased risk of venous thromboembolism (VTE), pulmonary hypertension, and mortality. 5,6 Pulmonary thromboembolism is the most common type of pulmonary embolism (PE), accounting for the vast majority (> 90%) of PE cases and is often referred to as PE. 7 Studies have found that patients with COPD are four times more likely to have PE than those without COPD, and patients with COPD combined with PE have significantly increased mortality. 8 In addition, according to research findings, erythrocyte distribution width (RDW), 9 mean platelet volume (MPV), 10 neutrophil-to-lymphocyte ratio (NLR), 11 and D-Dimer 12 and biomarkers such as fractalkine (FKN), 13 5-hydroxytryptamine (5-HT), 14 endothelin-1 (ET-1), 15 tissue plasminogen activator (t-PA), 16 tissue factor (TF), 17 and tissue factor pathway inhibitor (TFPI) 18 are risk factors associated with PE, which may play an important role in the pathogenesis of PE and have certain significance for clinical prognosis assessment. COPD has been identified as an independent risk factor for PE, with a significantly increased incidence of PE observed among COPD patients. 8 However, research pertaining to the risk factors and pathogenesis of PE in COPD patients with SP is lacking. Therefore, this study sought to investigate the prevalence of PE in COPD patients with SP, evaluate the risk factors for PE i -Abstract Truncated-
respiratory system